TY - JOUR
T1 - Nicotine and nicotinic receptor antagonists potentiate the antidepressant-like effects of imipramine and citalopram
AU - Popik, Piotr
AU - Kozela, Ewa
AU - Krawczyk, Martyna
PY - 2003/7
Y1 - 2003/7
N2 - 1. Epidemiological and clinical observations suggest the involvement of nicotinic acetylcholine receptors (nAChRs) in depressive illness. Nonetheless, there is no clearcut evidence that nicotine and/ or nAChR antagonists produce an antidepressant effect. 2. In the tail-suspension test (C57/Bl male mice), nicotine (0.8-1.2 mgkg -1 s.c. or i.p.) given 15-60 min before the measurement exerted no effect on immobility. 3. Given 30 min before the measurement, citalopram (2 mg kg -1) produced a slight decrease in immobility; coadministration of nicotine (0.8 mg kg -1, 15 but not 40 min before the test) to citalopram-treated mice resulted in a robust decrease in immobility. Imipramine (4 mg kg -1) did not affect immobility, but given in combination with 0.8 mg kg -1 of nicotine (15 but not 40 min before the test), a decrease in immobility was observed. Nicotine (0.8 and 1.2 mg kg -1) also produced an enhancement in the anti-immobility effect of imipramine (20 mg kg -1). 4. We further investigated if nAChR antagonists would influence the antidepressant-like effects of imipramine and citalopram. Unexpectedly, mecamylamine (1-2.5 mg kg -1) and dihydro-β-erythroidine (2 mg kg -1) potentiated the antidepressant-like effect of imipramine (4-20 mg kg -1). Mecamylamine (2.5 mg kg -1) but not dihydro-β-erythroidine also increased the antidepressant-like effect produced by 2 mg kg -1 of citalopram. 5. The interaction between nAChR antagonists and antidepressants appeared synergistic. 6. Neither nAChR ligands, antidepressants nor combinations of the two, affected locomotor activity. 7. The present results demonstrate an unexpected interaction between nAChR ligands and imipramine and citalopram in the tail-suspension test.
AB - 1. Epidemiological and clinical observations suggest the involvement of nicotinic acetylcholine receptors (nAChRs) in depressive illness. Nonetheless, there is no clearcut evidence that nicotine and/ or nAChR antagonists produce an antidepressant effect. 2. In the tail-suspension test (C57/Bl male mice), nicotine (0.8-1.2 mgkg -1 s.c. or i.p.) given 15-60 min before the measurement exerted no effect on immobility. 3. Given 30 min before the measurement, citalopram (2 mg kg -1) produced a slight decrease in immobility; coadministration of nicotine (0.8 mg kg -1, 15 but not 40 min before the test) to citalopram-treated mice resulted in a robust decrease in immobility. Imipramine (4 mg kg -1) did not affect immobility, but given in combination with 0.8 mg kg -1 of nicotine (15 but not 40 min before the test), a decrease in immobility was observed. Nicotine (0.8 and 1.2 mg kg -1) also produced an enhancement in the anti-immobility effect of imipramine (20 mg kg -1). 4. We further investigated if nAChR antagonists would influence the antidepressant-like effects of imipramine and citalopram. Unexpectedly, mecamylamine (1-2.5 mg kg -1) and dihydro-β-erythroidine (2 mg kg -1) potentiated the antidepressant-like effect of imipramine (4-20 mg kg -1). Mecamylamine (2.5 mg kg -1) but not dihydro-β-erythroidine also increased the antidepressant-like effect produced by 2 mg kg -1 of citalopram. 5. The interaction between nAChR antagonists and antidepressants appeared synergistic. 6. Neither nAChR ligands, antidepressants nor combinations of the two, affected locomotor activity. 7. The present results demonstrate an unexpected interaction between nAChR ligands and imipramine and citalopram in the tail-suspension test.
KW - Antidepressants
KW - Citalopram
KW - Depression
KW - Dihydro-β-erythroidine
KW - Imipramine
KW - Mecamylamine
KW - Mice
KW - Nicotinic receptors
KW - Tail-suspension test
KW - nAChR
UR - http://www.scopus.com/inward/record.url?scp=0042168756&partnerID=8YFLogxK
U2 - 10.1038/sj.bjp.0705359
DO - 10.1038/sj.bjp.0705359
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 12871839
AN - SCOPUS:0042168756
SN - 0007-1188
VL - 139
SP - 1196
EP - 1202
JO - British Journal of Pharmacology
JF - British Journal of Pharmacology
IS - 6
ER -